Quantification of Tacrolimus and Three Demethylated Metabolites in Human Whole Blood Using LC–ESI–MS/MS
- 1 April 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Therapeutic Drug Monitoring
- Vol. 34 (2), 134-142
- https://doi.org/10.1097/ftd.0b013e31824b0bfb
Abstract
A bioalanytical method for the quantification of tacrolimus (TAC) and 3 metabolites, 13-O, 15-O, and 31-O-demethylated TAC (M-I, M-III, and M-II) in human whole blood using liquid chromatography, electrospray ionization, tandem mass spectrometry (LC-ESI-MS/MS) was developed and validated. The analytes were extracted from 85 μL of blood by protein precipitation followed by solid-phase extraction and a concentration step. The analytes and the internal standard (IS, ascomycin) were separated on a C18 column using a slow gradient mobile phase elution, with an analysis time of 3.3 minutes. The ammonium-adduct ions with transitions of m/z 821.5 > 768.7 (TAC), 807.5 > 754.7 (M-I, M-III, M-II), and 809.4 > 756.7 (IS) were measured in selected reaction monitoring mode using electrospray ionization. Measuring ranges were 0.1-50 ng/mL for M-II, M-III, and TAC and 0.15-39 ng/mL for M-I. Imprecision in quantification was 50% for all analytes. The sample's stability was proven for 1 month at -20°C and 72 hours at room temperature. Three freeze-thaw cycles had no significant effect on the stability. The prepared samples were stable at least 16 hours at 8°C. Analysis of 53 patient samples resulted in average concentrations of 7.2 for TAC, 0.8 for M-I, 0.4 for M-III, and 0.2 ng/mL for M-II. The total metabolite concentration was 17% (4%-52%) of the TAC concentration. The TAC concentration measured by LC-MS/MS was 36.1% ± 27.1% lower than by immunochemical (enzyme multiplied immunoassay technique) analysis. When adding the metabolite crossreactivity in the presence of TAC, the difference between the 2 methods was still 29.8% ± 28.3%, indicating that the overestimation of TAC concentration of enzyme multiplied immunoassay technique compared with liquid chromatography-tandem mass spectrometry cannot only be ascribed to the demethylated metabolites. An LC-ESI-MS/MS method for the quantitative analysis of TAC and 3 metabolites, using a 2-step sample preparation was successfully developed, validated, and applied on 53 patient samples.Keywords
This publication has 24 references indexed in Scilit:
- Robust, High-Throughput LC-MS/MS Method for Therapeutic Drug Monitoring of Cyclosporine, Tacrolimus, Everolimus, and Sirolimus in Whole BloodTherapeutic Drug Monitoring, 2009
- Quantification of cyclosporine and tacrolimus in whole blood. Comparison of liquid chromatography–electrospray mass spectrometry with the enzyme multiplied immunoassay techniqueClinical Biochemistry, 2008
- Metabolism of Tacrolimus (FK506) and Recent Topics in Clinical PharmacokineticsDrug Metabolism and Pharmacokinetics, 2007
- EFFECT OFCYP3A5POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRODrug Metabolism and Disposition, 2006
- Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography–tandem mass spectrometryJournal of Chromatography B, 2006
- The EMIT 2000 tacrolimus assay: an application protocol for the Beckman Synchron LX20 PRO analyzerClinical Biochemistry, 2004
- TacrolimusDrugs, 2003
- Simplified High-Performance Liquid Chromatography-Mass Spectrometry Assay for Measurement of Tacrolimus and Its Metabolites and Cross-Validation with Microparticle Enzyme ImmunoassayTherapeutic Drug Monitoring, 1995
- Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.‐MS and microparticle enzyme immunoassay (MEIA).British Journal of Clinical Pharmacology, 1994
- Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomesBiochemical Pharmacology, 1994